The FDA, which has stopped short of requiring DPYD testing for patients before receiving fluoropyrimidines, emphasized the ...
The positive results from the second part of the EMBARK trial contrast with findings from one-year post treatment, which did ...
The trial will include patients with non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers.
With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.
In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...
BH-30643 is an OMNI-EGFR inhibitor that targets classical, atypical, and compound EGFR mutations and acquired resistance mutations in HER2.
NEW YORK – By the end of a controversial workshop Thursday on whether to test patients for genetic abnormalities that put them at risk of severe chemotherapy-related toxicities, oncologists seemed ...
The resolution aims to provide Illinois patients with equitable access to emerging treatments, including precision and genomic medicines.
The Shanghai-based firm will test the gene therapy candidate in patients between 4 and 9 years old with Duchenne muscular dystrophy.
The firm said it has received positive feedback from the FDA on the design of a Phase III trial of ELI-002 in KRAS-mutant pancreatic cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback